2015 VAM: 4307 - Sublingual Immunotherapy (SLIT): Current Perspectives
This recording provides the learner with a comprehensive understanding of the mechanisms of action, the results of properly controlled clinical studies, and the safety of sublingual immunotherapy treatment options that have either recently been licensed or are currently under investigation throughout the world.
AMA PRA Category 1 Credits™: 1.25
Credit must be claimed by June 30, 2017. Any credit request on or after July 1, 2017 will be subject to an administrative fee.
System requirements: Two most recent versions of Internet Explorer, Safari, Google Chrome, and Firefox
Allied Health Professionals
Upon completion of this activity, participants will be able to:
1. Describe the underlying mechanisms and actions of sublingual immunotherapy (SLIT) constructs
2. Identify how to properly evaluate and determine the maintenance treatment dose, the duration of therapy and the components of treatment when using SLIT
3. Discuss how to initiate appropriate treatment with the relevant therapeutic constructs that have recently received regulatory approval for use in the practice setting
Prof. Ronald Dahl, MD, Allergy Centre, Odense University Hospital, Odense, Denmark
Dr. Linda Cox, MD FAAAAI, Allergy & Asthma Center, Fort Lauderdale, FL
Dr. Désirée E.S. Larenas Linnemann, MD FAAAAI, Hospital Medica Sur, Mexico D.F., Mexico
- 1.25 AttendanceAttendance credit.
- 1.25 CECE credit.
- 1.25 CMECME credit.